JP2003043035A - Method for manufacturing liquid-like reagent raw material - Google Patents

Method for manufacturing liquid-like reagent raw material

Info

Publication number
JP2003043035A
JP2003043035A JP2001233939A JP2001233939A JP2003043035A JP 2003043035 A JP2003043035 A JP 2003043035A JP 2001233939 A JP2001233939 A JP 2001233939A JP 2001233939 A JP2001233939 A JP 2001233939A JP 2003043035 A JP2003043035 A JP 2003043035A
Authority
JP
Japan
Prior art keywords
liquid reagent
raw material
reagent
liquid
reagent raw
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001233939A
Other languages
Japanese (ja)
Inventor
Shinsuke Kimata
木全  伸介
Katsuhiko Mizuguchi
水口  克彦
Masanori Oka
岡  正則
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toyobo Co Ltd
Original Assignee
Toyobo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyobo Co Ltd filed Critical Toyobo Co Ltd
Priority to JP2001233939A priority Critical patent/JP2003043035A/en
Publication of JP2003043035A publication Critical patent/JP2003043035A/en
Withdrawn legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To provide a method for manufacturing a liquid reagent raw material and a composition, especially a manufacturing method of a stable reagent raw material having non-prepared liquid reagents in a clinical inspection field, and a composition using the method. SOLUTION: In the manufactured of the liquid reagent raw material by mixing at least two types of constituents, each constituent is mixed in a dry state without being dissolved.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は液状試薬原料の製造
方法および組成物に関する。特に、臨床検査分野で用い
られる無調製液状試薬の安定な試薬原料の製造方法およ
びそれを用いた組成物に関する。
TECHNICAL FIELD The present invention relates to a method and a composition for producing a liquid reagent raw material. In particular, it relates to a method for producing a stable reagent raw material for an unprepared liquid reagent used in the field of clinical examination, and a composition using the same.

【0002】[0002]

【従来の技術】臨床検査分野で用いられる診断薬として
酵素反応を利用した生化学的測定試薬がある。本試薬で
は、酵素が溶液中で不安定なため、酵素および酵素以外
の不安定物質を凍結乾燥し、使用前に溶解液で溶解し使
用していた。このため、製造側では凍結乾燥を行うこと
からコスト、製造時間がかかり、また使用者側では溶解
の手間がかかるという問題があった。
2. Description of the Related Art As a diagnostic agent used in the field of clinical examination, there is a biochemical measuring reagent utilizing an enzymatic reaction. In this reagent, since the enzyme is unstable in the solution, the enzyme and the unstable substance other than the enzyme were freeze-dried and dissolved in the solution before use. Therefore, there is a problem in that the manufacturing side requires freeze-drying, which results in cost and manufacturing time, and the user side requires time and effort for dissolution.

【0003】これに対し、近年、調製不要の無調製液状
試薬が開発され凍結乾燥に伴う問題点を解決した。本液
状試薬は種々の方法により原料酵素、補酵素等の安定化
を行うことで、溶液状態で長期間保存可能な試薬として
完成され、現在では国内の生化学的測定試薬市場では主
流になっている。
On the other hand, in recent years, an unprepared liquid reagent which does not require preparation has been developed to solve the problems associated with freeze-drying. This liquid reagent was completed as a reagent that can be stored in solution for a long period of time by stabilizing the raw material enzymes, coenzymes, etc. by various methods, and is now the mainstream in the domestic biochemical measurement reagent market. There is.

【0004】本試薬が商品として成り立つ背景として国
内の良好な流通事情が大きく起因していると考えられ
る。つまり、国内では地理的に少なくとも2日以内に冷
蔵状態で配送が可能であることである。このことから、
液状試薬の商品設計としては低温で1年程度品質を保持
するものであれば必要十分である。
It is considered that the good distribution circumstances in Japan are largely responsible for the reason why this reagent becomes a commercial product. In other words, it is possible to deliver in a refrigerated state within at least two days geographically in Japan. From this,
As for the product design of the liquid reagent, it is necessary and sufficient if it can maintain the quality at low temperature for about one year.

【0005】しかし、本液状試薬を海外に輸出する場
合、状況が異なる。つまり、輸出の場合、低温での流通
は可能であるが手続き等を含め輸送日数がかかる。更に
輸出先ではその国の流通事情により保存温度の保証は十
分得られないのが実状である。このことから、現設計の
液状試薬では海外輸出先で国内と同等の品質保持期間お
よび性能が得られないという問題がある。
However, the situation is different when the present liquid reagent is exported overseas. In other words, in the case of export, distribution at low temperature is possible, but the number of days required for transportation, including procedures, is required. Furthermore, it is the actual situation that the storage temperature cannot be sufficiently guaranteed at the export destination due to the distribution circumstances of the country. For this reason, the liquid reagent of the present design has a problem that the quality retention period and performance equivalent to those in Japan cannot be obtained at overseas export destinations.

【0006】また、品質以外の点においても液状試薬で
あることから粉末に比べ重く輸送コストがかかり、また
輸送時の振動等により容器破損、液漏れ等の問題もあ
る。
In addition to the quality, since it is a liquid reagent in terms of quality, it is heavier than powder and costs more to transport, and there are problems such as container damage and liquid leakage due to vibration during transportation.

【0007】また、本液状試薬の製造工程においては各
原料試薬の調製が最もリードタイムを要することから工
程改善の必要がある。
Further, in the manufacturing process of the present liquid reagent, preparation of each raw material reagent requires the longest lead time, and therefore it is necessary to improve the process.

【0008】[0008]

【発明が解決しようとする課題】本発明が解決しようと
する課題は、無調製液状試薬に用いられる安定な試薬原
料およびその製造方法を提供することであり、更には液
状試薬の製造工程の省力化に寄与する長期間安定な液状
試薬原料を提供することにある。
The problem to be solved by the present invention is to provide a stable reagent raw material used for an unprepared liquid reagent and a method for producing the same, and further labor saving in the process for producing the liquid reagent. The purpose of the present invention is to provide a stable liquid reagent raw material for a long period of time that contributes to the realization.

【0009】[0009]

【課題を解決するための手段】本発明者らは、上記目的
を達成するために種々検討した結果、2種以上の成分を
溶解することなく乾燥状態で均一に混合することによ
り、長期間安定な液状試薬原料を作製し、かつそれを用
いたキットも長期間安定であることを見出し、本発明を
完成した。すなわち、本発明は以下のような構成からな
る。 (1)2種以上の成分を混合してなる液状試薬原料の製
造において、各成分を溶解することなく乾燥状態で混合
することを特徴とする液状試薬原料の製造方法。 (2)液状試薬原料が均一に混合されていることを特徴
とする、(1)の液状試薬原料の製造方法。 (3)緩衝剤を少なくとも10%(w/w)含有する、
(1)、(2)の液状試薬原料の製造方法。 (4)緩衝剤を50%(w/w)以上含有する、(1)
〜(3)の液状試薬原料の製造方法。 (5)2種以上の成分が溶解されることなく乾燥状態で
混合された液状試薬原料組成物。 (6)液状試薬原料が均一に混合されている(5)の液
状試薬原料組成物。 (7)緩衝剤を少なくとも10%(w/w)含有する、
(5)、(6)の液状試薬原料組成物。 (8)緩衝剤を50%(w/w)以上含有する、(5)
〜(7)の液状試薬原料組成物。 (9)2種以上の成分が緩衝剤、酵素、補酵素、酵素基
質、色源体、防腐剤、金属塩、界面活性剤、安定化剤よ
り選ばれた物質である(5)〜(8)の液状試薬原料組
成物。 (10)所定量の水または試液で溶解して用いられる
(5)〜(9)の液状試薬原料組成物。 (11)少なくとも2種の成分を混合してなる液状試薬
において、予め少なくとも2種以上の成分よりなる液状
試薬原料を調製して、一定期間保持した後、所定量の水
または試液で溶解して液状試薬を完成させ、測定に供せ
しめる液状試薬原料であって、該液状試薬原料を37
℃、2週間保存後、所定量の水または試液で溶解した液
状試薬の測定感度が、保存前の測定感度に対し80%以
上保持し、さらに該液状試薬を35℃、1週間保存した
後の測定感度が、保存前の測定感度に対し80%以上保
持することを特徴とする(5)〜(10)の液状試薬原
料組成物。 (12)液状試薬原料を分析機で用いる容器に所定の用
量を小分封し、該容器に所定量の水または試液を加え溶
解して用いられる(5)〜(11)の液状試薬原料組成
物。 (13)液状試薬がクレアチニン測定試薬である(5)
〜(12)の液状試薬原料組成物。 (14)液状試薬が中性脂肪測定試薬である(5)〜
(12)の液状試薬原料組成物。 (15)液状試薬がコレステロール測定試薬である
(5)〜(12)の液状試薬原料組成物。 (16)液状試薬が尿酸測定試薬である(5)〜(1
2)の液状試薬原料組成物。
Means for Solving the Problems As a result of various studies for achieving the above-mentioned object, the present inventors have made it possible to obtain long-term stability by mixing two or more components in a dry state without dissolving them. The present inventors have completed the present invention by producing a simple liquid reagent raw material and finding that a kit using the same is stable for a long period of time. That is, the present invention has the following configurations. (1) A method for producing a liquid reagent raw material, which comprises mixing two or more components in a dry state without dissolving each component in the production of the liquid reagent raw material. (2) The method for producing a liquid reagent raw material according to (1), wherein the liquid reagent raw material is uniformly mixed. (3) contains at least 10% (w / w) buffer,
The method for producing a liquid reagent raw material according to (1) or (2). (4) Containing 50% (w / w) or more of a buffer, (1)
~ The method for producing a liquid reagent raw material according to (3). (5) A liquid reagent raw material composition in which two or more components are mixed in a dry state without being dissolved. (6) The liquid reagent raw material composition according to (5), in which the liquid reagent raw materials are uniformly mixed. (7) contains at least 10% (w / w) buffer,
The liquid reagent raw material composition according to (5) or (6). (8) Containing 50% (w / w) or more of a buffer, (5)
~ The liquid reagent raw material composition according to (7). (9) Two or more kinds of components are substances selected from buffers, enzymes, coenzymes, enzyme substrates, chromogens, preservatives, metal salts, surfactants, and stabilizers (5) to (8) ) Liquid reagent raw material composition. (10) The liquid reagent raw material composition according to (5) to (9), which is used after being dissolved in a predetermined amount of water or a reagent solution. (11) In a liquid reagent prepared by mixing at least two kinds of components, a liquid reagent raw material composed of at least two kinds of components is prepared in advance, held for a certain period, and then dissolved with a predetermined amount of water or a test solution. A liquid reagent raw material which is used to complete a liquid reagent and to be used for measurement.
After being stored at 2 ° C for 2 weeks, the measurement sensitivity of the liquid reagent dissolved in a predetermined amount of water or a reagent solution is 80% or more of the measurement sensitivity before storage, and the liquid reagent after stored at 35 ° C for 1 week The liquid reagent raw material composition according to (5) to (10), wherein the measurement sensitivity is 80% or more of the measurement sensitivity before storage. (12) Liquid reagent raw material composition according to (5) to (11), which is used by subdividing a predetermined dose of a liquid reagent raw material into a container used in an analyzer, and adding and dissolving a predetermined amount of water or a reagent solution to the container. . (13) The liquid reagent is a creatinine measurement reagent (5)
~ (12) liquid reagent raw material composition. (14) The liquid reagent is a neutral fat measuring reagent (5) to
The liquid reagent raw material composition according to (12). (15) The liquid reagent raw material composition according to (5) to (12), wherein the liquid reagent is a cholesterol measuring reagent. (16) The liquid reagent is a uric acid measuring reagent (5) to (1
Liquid reagent raw material composition of 2).

【0010】[0010]

【発明の実施の形態】本発明の一実施態様として、緩衝
剤、酵素、補酵素、酵素基質、色源体、防腐剤、金属
塩、界面活性剤、安定化剤等を含む臨床検査用液状試薬
原料がある。
BEST MODE FOR CARRYING OUT THE INVENTION As one embodiment of the present invention, a liquid for clinical examination containing a buffer, an enzyme, a coenzyme, an enzyme substrate, a chromogen, a preservative, a metal salt, a surfactant, a stabilizer and the like. There is a reagent raw material.

【0011】本発明の液状試薬原料は、緩衝剤、酵素、
補酵素、酵素基質、色源体、防腐剤、金属塩、界面活性
剤、安定化剤等より選ばれた2種以上の成分を、溶解す
ることなく乾燥状態で混合し製造される。好ましくは、
復元後の液状試薬の性能を目安に均一に混合される。復
元後の性能としては、例えば、液状試薬原料より所定量
を無作為にN=3で秤量し、所定量の水または試液で溶
解した液状試薬の測定感度が許容範囲であることを目安
とする。許容範囲としては、N=3の感度の幅が40%
以内、好ましくは20%以内である。製造環境として
は、例えば、温度、湿度等が管理された低湿度室等で製
造されるのが好ましい。具体的には、湿度は60%以
下、好ましくは50%以下、さらに好ましくは40%以
下であり、温度は40℃以下、好ましくは30℃以下で
ある。また、各々の成分の混合は、第一に緩衝剤、酵
素、補酵素、酵素基質、色源体、防腐剤、金属塩、界面
活性剤、安定化剤等より選ばれた2種以上の成分を、密
封可能な容器(各成分の容器へ吸着を抑える目的で、放
電処理を行ったものがよい)に所定量入れ、ローター等
を用いよく混合する。この時、各々の成分は、粒度の大
きいものは予め乳鉢等ですりつぶすか、一定以下の粒度
になるようにふるいにかけて粒度を合わせることで、各
々の成分をより均一に混合することができる。該液状試
薬原料は、液状試薬の1構成に対し1種に限らず、2種
以上の原料を混合して完成させることもある。また液状
試薬の復元方法は特に限定されないが、精製水等や、液
状試薬原料に含まれない成分または室温下で個体状態を
保てない成分を含む試液も用いられる。復元に液体を用
いることにより復元工程が省力化される利点がある。特
に精製水を用いる場合復元工程が大幅に省力化される。
The liquid reagent raw material of the present invention comprises a buffer, an enzyme,
It is produced by mixing two or more kinds of components selected from coenzyme, enzyme substrate, chromogen, preservative, metal salt, surfactant and stabilizer in a dry state without being dissolved. Preferably,
It is mixed uniformly based on the performance of the liquid reagent after restoration. As for the performance after reconstitution, for example, a predetermined amount of liquid reagent raw material is randomly weighed at N = 3, and the measurement sensitivity of the liquid reagent dissolved in the predetermined amount of water or reagent solution is within the allowable range. . As the allowable range, the sensitivity range of N = 3 is 40%.
Within, preferably within 20%. As a manufacturing environment, for example, it is preferable to manufacture in a low humidity room or the like in which temperature, humidity and the like are controlled. Specifically, the humidity is 60% or less, preferably 50% or less, more preferably 40% or less, and the temperature is 40 ° C. or less, preferably 30 ° C. or less. In addition, the respective components are mixed by mixing two or more kinds of components selected from a buffer, an enzyme, a coenzyme, an enzyme substrate, a chromogen, an antiseptic, a metal salt, a surfactant, a stabilizer and the like. Is placed in a hermetically sealed container (which is preferably subjected to a discharge treatment for the purpose of suppressing adsorption of each component into the container) and mixed well by using a rotor or the like. At this time, each of the components having a large particle size can be ground in advance with a mortar or the like, or the particles can be mixed more uniformly by sieving so that the particle size is below a certain level. The liquid reagent raw material is not limited to one kind for one constitution of the liquid reagent, but may be completed by mixing two or more kinds of raw materials. Although the method for reconstituting the liquid reagent is not particularly limited, purified water or the like, or a reagent solution containing a component that is not contained in the liquid reagent raw material or a component that cannot maintain a solid state at room temperature is also used. The use of the liquid for the restoration has the advantage of saving labor in the restoration process. In particular, when using purified water, the restoration process is greatly labor-saving.

【0012】本発明に使用される緩衝剤としては、特に
限定されないが、トリス緩衝剤、クエン酸緩衝剤、リン
酸緩衝剤、ほう酸ホウ砂緩衝剤、GOOD緩衝剤などが
挙げられる。なかでも、トリス緩衝剤、クエン酸緩衝
剤、ほう酸ホウ砂緩衝剤、リン酸緩衝剤は濃度、温度に
よってpHが変動しやすいが、安価であるという利点が
ある。また、GOOD緩衝剤にはMES、Bis−Tr
is、ADA、ACES、BES、PIPES、MOP
S、TES、HEPES、Tricine、Bicin
e、POPSO、TAPS、CHES、CAPSなどが
例示される。また、これら緩衝剤は液状試薬復元後、目
的のpHになるように濃度または各塩で調製されうる。
例えばりん酸緩衝剤ではりん酸1水素2Na塩とりん酸
2水素K塩との混合、トリス緩衝液では塩酸塩との混
合、GOOD緩衝剤ではNa塩との混合比率を変えて調
製されうる。
The buffer used in the present invention is not particularly limited, but examples thereof include Tris buffer, citrate buffer, phosphate buffer, borate borax buffer, GOOD buffer and the like. Among them, the Tris buffer, the citrate buffer, the borax borates buffer, and the phosphate buffer have an advantage that they are inexpensive although the pH easily changes depending on the concentration and temperature. In addition, GOS buffer is MES, Bis-Tr
is, ADA, ACES, BES, PIPES, MOP
S, TES, HEPES, Tricine, Bicin
e, POPSO, TAPS, CHES, CAPS, etc. are exemplified. In addition, these buffers may be prepared in concentrations or salts so that the target pH is obtained after the liquid reagent is reconstituted.
For example, a phosphate buffer may be prepared by mixing a dihydrogen phosphate 2Na salt and a dihydrogen phosphate K salt, a Tris buffer solution with a hydrochloride salt, and a GOOD buffer solution with a mixture ratio with a Na salt.

【0013】本発明に使用される緩衝剤の濃度として
は、特に限定されないが、通常、共存する他の成分に対
し少なくとも10%(w/w)、好ましくは(各成分を
均一に混合する観点から)50%(w/w)以上含有す
るのが望ましい。
The concentration of the buffer used in the present invention is not particularly limited, but it is usually at least 10% (w / w) with respect to other coexisting components, preferably (from the viewpoint of uniformly mixing the components ) . Therefore, it is desirable to contain 50% (w / w) or more.

【0014】本発明に使用される酵素は微生物、植物、
哺乳動物から採取されるもの、またはこれらの遺伝子を
他の微生物に組み込まれた遺伝子組換え微生物より製造
されたものなどがあり、また、遺伝子的に性質を改変し
たものを含有するが特に限定されない。
The enzymes used in the present invention are microorganisms, plants,
Examples include those collected from mammals, those produced from genetically modified microorganisms in which these genes are incorporated into other microorganisms, and those containing genetically modified properties are not particularly limited. .

【0015】本発明に用いられる補酵素としては、ニコ
チンアミドアデニンジヌクレオチド、フラビンアデニン
ジヌクレンチド、ピリドキサールリン酸、アデノシン3
リン酸、アデノシン2リン酸等が例示される。
The coenzyme used in the present invention includes nicotinamide adenine dinucleotide, flavin adenine dinuclentide, pyridoxal phosphate, and adenosine 3
Examples include phosphoric acid and adenosine diphosphate.

【0016】本発明に用いられる酵素基質としては特に
限定されないが、α−ケトグルタル酸、ホスホエノール
ピルビン酸、クレアチンリン酸、2−ケトイソヘキサン
酸、L−アスパラギン酸、L−α−アラニン等が挙げら
れる。
The enzyme substrate used in the present invention is not particularly limited, but α-ketoglutarate, phosphoenolpyruvate, creatine phosphate, 2-ketoisohexanoic acid, L-aspartic acid, L-α-alanine and the like are used. Can be mentioned.

【0017】本発明に用いられる色源体としては、酸化
系発色試薬、還元系発色試薬、トリンダー試薬およびそ
のカプラー等が例示される。酸化系発色試薬試薬として
は、ヘキサ(2−ヒドロキシ−3−スルホプロピル)−
4,4,4,−トリアミノトリフェニルメタン、ヘキサ
(3−スルホプロピル)−4,4,4−トリアミノトリ
フェニルメタン、ビス(2−ヒドロキシ−3−スルホプ
ロピル)トルイジン等が挙げられる。還元系発色試薬と
しては、例えばテトラゾリウム塩類が挙げられ、IN
T、MTT、TB、WST−1、WST−3、WST−
5等が挙げられ1−m−PMS等の電子キャリアーと組
み合わせて用いられる。トリンダー試薬としては、N−
エチル−N−スルホプロピル−m−アニシジン、N−エ
チル−N−スルホプロピルアニリン、N−エチル−N−
スルホプロピル−3,5−ジメトキシアニリン、N−ス
ルホプロピル−3,5−ジメチルアニリン、N−エチル
−N−スルホプロピル−3,5−ジメチルアニリン、N
−エチル−N−スルホプロピル−m−トルイジン、N−
エチル−N−(2−ヒドロキシ−3−スルホプロピル)
−m−アニシジン、N−エチル−N−(2−ヒドロキシ
−3−スルホプロピル)アニリン、N−エチル−N−
(2−ヒドロキシ−3−スルホプロピル)−3,5−ジ
メトキシアニリン、N−(2−ヒドロキシ−3−スルホ
プロピル)−3,5−ジメトキシアニリン、N−エチル
−N−(2−ヒドロキシ−3−スルホプロピル)−3,
5−ジメチルアニリン、N−エチル−N−(2−ヒドロ
キシ−3−スルホプロピル)−m−トルイジン、N−ス
ルホプロピルアニリンが挙げられる。そのカプラーとし
ては4−アミノアンチピリン、MBTH等が挙げられ
る。
Examples of the color source used in the present invention include an oxidative coloring reagent, a reducing coloring reagent, a Trinder reagent and a coupler thereof. Oxidative color reagent Reagents include hexa (2-hydroxy-3-sulfopropyl)-
4,4,4-triaminotriphenylmethane, hexa (3-sulfopropyl) -4,4,4-triaminotriphenylmethane, bis (2-hydroxy-3-sulfopropyl) toluidine and the like can be mentioned. Examples of the reducing color reagent include tetrazolium salts.
T, MTT, TB, WST-1, WST-3, WST-
5 and the like, which are used in combination with an electron carrier such as 1-m-PMS. As a Trinder reagent, N-
Ethyl-N-sulfopropyl-m-anisidine, N-ethyl-N-sulfopropylaniline, N-ethyl-N-
Sulfopropyl-3,5-dimethoxyaniline, N-sulfopropyl-3,5-dimethylaniline, N-ethyl-N-sulfopropyl-3,5-dimethylaniline, N
-Ethyl-N-sulfopropyl-m-toluidine, N-
Ethyl-N- (2-hydroxy-3-sulfopropyl)
-M-anisidine, N-ethyl-N- (2-hydroxy-3-sulfopropyl) aniline, N-ethyl-N-
(2-Hydroxy-3-sulfopropyl) -3,5-dimethoxyaniline, N- (2-hydroxy-3-sulfopropyl) -3,5-dimethoxyaniline, N-ethyl-N- (2-hydroxy-3) -Sulfopropyl) -3,
Examples thereof include 5-dimethylaniline, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-toluidine, and N-sulfopropylaniline. Examples of the coupler include 4-aminoantipyrine and MBTH.

【0018】本発明に用いられる防腐剤としては、アジ
化物、キレート剤、抗生物質、抗菌剤などが挙げられ
る。抗菌剤としては、MIT、HPO、CAA、IZ
U、BND等が挙げられる。
Examples of the preservatives used in the present invention include azides, chelating agents, antibiotics and antibacterial agents. Antibacterial agents include MIT, HPO, CAA, IZ
U, BND, etc. are mentioned.

【0019】本発明に用いられる金属塩としては、特に
限定されないが、ナトリウム、カリウム、カルシウム等
の塩類が挙げられ、NaCl、KCl、CaCl2等が
挙げられる。
The metal salt used in the present invention is not particularly limited, but salts such as sodium, potassium, calcium and the like, such as NaCl, KCl, CaCl 2 and the like can be mentioned.

【0020】本発明に用いられる界面活性剤としては、
特に限定されないが、非イオン界面活性剤、陽イオン界
面活性剤、陰イオン界面活性剤、両性イオン界面活性剤
が挙げられる。非イオン界面活性剤としては、N,N−
ビス(3−D−グルコアミドプロピル)コラミド、n−
ヘプチル−β−D−チオグルコシド、n−オクチル−β
−D−チオグコシド、MEGA−8、MEGA−9、M
EGA−10、シュークロースモノカプレートが挙げら
れる。陽イオン界面活性剤としては、SDSが挙げられ
る。陰イオン界面活性剤としては、コール酸ナトリウ
ム、両性イオン界面活性剤としては、CHAPS、CH
APSOが挙げられる。
The surfactant used in the present invention includes:
Non-limiting examples include nonionic surfactants, cationic surfactants, anionic surfactants and zwitterionic surfactants. As the nonionic surfactant, N, N-
Bis (3-D-glucoamidopropyl) colamide, n-
Heptyl-β-D-thioglucoside, n-octyl-β
-D-thiogukoside, MEGA-8, MEGA-9, M
Examples include EGA-10 and sucrose monoca plate. Examples of the cationic surfactant include SDS. Sodium cholate is used as the anionic surfactant, and CHAPS, CH is used as the zwitterionic surfactant.
APSO is mentioned.

【0021】本発明に用いられる安定化剤としては、特
に限定されないが、チオール化合物、フラビン含有化合
物、糖類、アルブミン、キレート剤等の公知の各安定化
剤が挙げられる。
The stabilizer used in the present invention is not particularly limited, and examples thereof include known stabilizers such as thiol compounds, flavin-containing compounds, saccharides, albumin and chelating agents.

【0022】本発明の別の一実施態様は、調製後、一定
期間保持した後、追加成分を添加して液状試薬を完成
(復元)させ、測定に供せしめる液状試薬原料である。
一定期間の保持には、保存または移動が含まれる。具体
的には、工場やその隣接地にある保管庫・倉庫などにお
ける保管や、トラック・鉄道・航空機・船舶等あるいは
人手による移送、さらには移送先での保管庫・倉庫など
における保管などが挙げられる。
Another embodiment of the present invention is a liquid reagent raw material which is prepared and held for a certain period of time, and then an additional component is added to complete (reconstitute) the liquid reagent to be used for measurement.
Retention for a period of time includes storing or moving. Specific examples include storage in factories and storage areas and warehouses adjacent to it, transportation by trucks, railroads, aircraft, ships, etc. or by humans, and storage at storage areas such as storage areas and warehouses. To be

【0023】保持の期間については、特に限定されない
が、流通事情などを考慮すると、10℃以下の低温では
6ヶ月以上、さらに好ましくは1年以上である。保持期
間中の温度については特に限定されないが、好ましくは
10℃以下、さらに好ましくは0℃以下、さらには−2
0℃以下である。実際の評価においては、上記保存期間
は高温での短期間の保存、例えば37℃2週間の過酷
(加速)試験をもって代用する場合もある。この方法で
は、長期保存安定性と同時に、移送時などに一時的に高
温下にさらされる可能性等を考慮した比較的短期間の高
温耐性をも合わせて評価できる利点がある。本発明で
は、例えば、液状試薬原料を37℃、2週間保存後、所
定量の水または試液で溶解した液状試薬の測定感度が、
保存前の測定感度に対し80%以上保持される。
Although the holding period is not particularly limited, it is 6 months or longer, and more preferably 1 year or longer at a low temperature of 10 ° C. or lower in consideration of distribution circumstances. The temperature during the holding period is not particularly limited, but is preferably 10 ° C or lower, more preferably 0 ° C or lower, and further -2.
It is 0 ° C or lower. In the actual evaluation, the storage period may be replaced by a short-term storage at high temperature, for example, a severe (accelerated) test at 37 ° C. for 2 weeks. This method has an advantage that it is possible to evaluate not only long-term storage stability but also relatively short-term high temperature resistance considering the possibility of being temporarily exposed to high temperature during transportation. In the present invention, for example, after the liquid reagent raw material is stored at 37 ° C. for 2 weeks, the measurement sensitivity of the liquid reagent dissolved in a predetermined amount of water or a reagent solution is
80% or more of the measurement sensitivity before storage is maintained.

【0024】本発明の液状試薬原料を一定期間保持した
後、復元した液状試薬は、予めすべての成分を調製して
できた同組成の液状試薬と同等の品質保持期間および性
能を示す。例えば、該液状試薬を35℃、1週間保存し
た後の測定感度が、保存前の測定感度に対し80%以上
保持される。
After the liquid reagent raw material of the present invention is held for a certain period of time, the reconstituted liquid reagent exhibits the same quality holding period and performance as the liquid reagent of the same composition prepared by preparing all the components in advance. For example, the measurement sensitivity after storing the liquid reagent at 35 ° C. for 1 week is 80% or more of the measurement sensitivity before storage.

【0025】本発明の液状試薬原料を復元する際には、
その全部を復元しても良いし、一部分を分取して復元し
ても良い。本発明の液状試薬原料は成分が均一に混合さ
れているため、一部分を分取して復元する工程を繰り返
したときの試薬性能のばらつきが小さい利点がある。
When restoring the liquid reagent raw material of the present invention,
All of them may be restored, or a part of them may be sorted and restored. Since the components of the liquid reagent raw material of the present invention are uniformly mixed, there is an advantage that there is little variation in reagent performance when the process of separating and restoring a part is repeated.

【0026】本発明に係る液状試薬原料の用途としては
生体成分中の尿酸、クレアチニン、中性脂肪、コレステ
ロール、尿素窒素等の測定に用いられる液状試薬等が挙
げられる。これら液状試薬の構成は特に限定されず、1
試液または2試液以上のキットとして用いられる。
Examples of the use of the liquid reagent raw material according to the present invention include a liquid reagent used for measuring uric acid, creatinine, neutral fat, cholesterol, urea nitrogen and the like in biological components. The configuration of these liquid reagents is not particularly limited, and 1
Used as a test solution or a kit of two or more test solutions.

【0027】[0027]

【実施例】以下、本発明を実施例により具体的に説明す
る。なお、本発明は実施例により特に限定されるもので
はない。
EXAMPLES The present invention will be specifically described below with reference to examples. The present invention is not particularly limited to the examples.

【0028】(実施例1)下記の2試薬からなる尿酸測
定液状試薬原料を作製した。 〈尿酸測定液状試薬原料の調製〉 第1試薬(液状試薬として1L分) リン酸水素2ナトリウム 8.5g、リン酸2水素ナト
リウム 5.5g、EDTA・3Na 0.025g、
BSA 0.5g、4−アミノアンチピリン 0.4
g、ペルオキシダーゼ(東洋紡製PEO−301)
0.01g、アスコルビン酸オキシダーゼ(東洋紡製A
SO−311) 0.02gを低湿度室にて均一に混合
し液状試薬原料とした。 第2試薬(液状試薬として1L分) リン酸水素2ナトリウム 8.5g、リン酸2水素ナト
リウム 5.5g、EDTA・3Na 0.025g、
BSA 0.5g、フェロシアン化カリウム 0.1
g、N−エチル−N−(2−ヒドロキシ−3−スルホプ
ロピル)−m−トルイジン 0.4g/L、ウリカーゼ
(東洋紡製UAO−211) 0.2gを低湿度室にて
均一に混合し液状試薬原料とした。上記原料を直ちに精
製水で溶解した液状試薬および液状試薬原料の状態で−
20℃で1年間保存し、保存後精製水で溶解した液状試
薬を用い、10mg/dLの尿酸水溶液を測定した。
(Example 1) A liquid reagent raw material for measuring uric acid comprising the following two reagents was prepared. <Preparation of Uric Acid Measuring Liquid Reagent Raw Material> First Reagent (1 L as Liquid Reagent) Disodium Hydrogen Phosphate 8.5 g, Sodium Dihydrogen Phosphate 5.5 g, EDTA.3Na 0.025 g,
BSA 0.5 g, 4-aminoantipyrine 0.4
g, peroxidase (TOYOBO PEO-301)
0.01 g, ascorbate oxidase (Toyobo A
SO-311) 0.02 g was uniformly mixed in a low humidity chamber to prepare a liquid reagent raw material. Second reagent (1 L portion as liquid reagent) 8.5 g of disodium hydrogen phosphate, 5.5 g of sodium dihydrogen phosphate, 0.025 g of EDTA.3Na,
BSA 0.5 g, potassium ferrocyanide 0.1
g, N-ethyl-N- (2-hydroxy-3-sulfopropyl) -m-toluidine 0.4 g / L, uricase (TOYOBO UAO-211) 0.2 g are evenly mixed in a low humidity chamber to form a liquid. It was used as a reagent raw material. In the state of liquid reagent and liquid reagent raw material in which the above raw material is immediately dissolved in purified water-
It was stored at 20 ° C. for 1 year, and after storage, a 10 mg / dL uric acid aqueous solution was measured using a liquid reagent dissolved in purified water.

【0029】〈測定法〉日立7170形自動分析機を用
いた。試料4μLに第一試薬 180μL添加し37℃
にて5分間インキュベーションし第一反応とした。その
後第二試薬を90μL添加し5分間インキュベーション
し第二反応とした。第一反応および第二反応の吸光度を
液量補正した各吸光度の差をとる2ポイントエンド法で
600nmにおける吸光度を測定した。結果は、精製水
の測定吸光度を差し引いた測定吸光度(感度)として求
めた。
<Measurement method> A Hitachi 7170 type automatic analyzer was used. 180 μL of the first reagent was added to 4 μL of the sample and 37 ° C.
It was incubated for 5 minutes in the reaction to make it the first reaction. After that, 90 μL of the second reagent was added and incubated for 5 minutes to give a second reaction. The absorbance at 600 nm was measured by the 2-point end method in which the absorbance of the first reaction and the absorbance of the second reaction were liquid-corrected and the difference between the absorbances was taken. The result was determined as the measured absorbance (sensitivity) after subtracting the measured absorbance of purified water.

【0030】結果 表1に示す。結果は液状試薬原料
を作製後直ちに溶解した試薬(実施例1−)の測定感
度を100としたときの、作製後−20℃、1年間保存
した液状試薬原料を復元した試薬(実施例1−)の測
定感度の相対値を示す。調製後から復元までの良好な保
存安定性を確認できた。
Results are shown in Table 1. The results show that when the measurement sensitivity of the reagent (Example 1-) in which the liquid reagent raw material was immediately dissolved after preparation was 100, the liquid reagent raw material stored for 1 year at -20 ° C after preparation was restored (Example 1-). ) Shows the relative value of the measurement sensitivity. Good storage stability from the preparation to the restoration was confirmed.

【0031】[0031]

【表1】 [Table 1]

【0032】(実施例2)実施例1で復元した液状試薬
を10℃で1年間保存し、実施例1と同様に10mg/
dLの尿酸水溶液を測定した。方法は実施例1と同様に
行った。
(Example 2) The liquid reagent reconstituted in Example 1 was stored at 10 ° C for 1 year, and 10 mg / mg was stored in the same manner as in Example 1.
A dL aqueous solution of uric acid was measured. The method was the same as in Example 1.

【0033】結果 表1に示す。実施例2−、は
各々実施例1−、の溶解後の試薬をさらに10℃、
1年間保存したときの測定感度の実施例1−を100
としたときの相対値を示す。復元後の良好な保存安定性
を確認できた。
Results are shown in Table 1. In Example 2-, the reagent after dissolution in Example 1- was further added at 10 ° C,
Example 1 of measurement sensitivity when stored for 1 year 100-
Indicates the relative value when. It was possible to confirm good storage stability after restoration.

【0034】(実施例3)下記の2試薬からなるクレア
チニン測定液状試薬原料を作製した。 〈クレアチニン測定液状試薬原料の調製〉 第1試薬(液状試薬として1L分) リン酸水素2ナトリウム 11.92g、リン酸2水素
カリウム 2.16g、EDTA・3Na 0.2g、
NaCl 3.3g、N−エチル−N−スルホプロピル
−m−トルイジン 0.14g、アスコルビン酸オキシ
ダーゼ(東洋紡製ASO−311) 0.02g、ザル
コシンオキシダーゼ(東洋紡製SAO−341) 0.
6g、、クレアチンアミジノヒドロラーゼ(東洋紡製C
RH−221) 2.7g、を低湿度室にて均一に混合
し液状試薬原料とした。 第2試薬(液状試薬として1L分) リン酸水素2ナトリウム 11.92g、リン酸2水素
カリウム 2.16g、4−アミノアンチピリン 0.
4g、ペルオキシダーゼ(東洋紡製PEO−301)
0.07g、クレアチニンアミドヒドロラーゼ(東洋紡
製CNH−311) 1.2gを低湿度室にて均一に混
合し液状試薬原料とした。上記原料を直ちに下記溶解液
で溶解した液状試薬および液状試薬原料の状態で−20
℃で1年間保存し、保存後下記溶解液で溶解した液状試
薬を用い、5mg/dLのクレアチニン水溶液を測定し
た。
Example 3 A liquid reagent raw material for creatinine measurement consisting of the following two reagents was prepared. <Preparation of Creatinine Measurement Liquid Reagent Raw Material> First Reagent (1 L as Liquid Reagent) Disodium Hydrogen Phosphate 11.92 g, Potassium Dihydrogen Phosphate 2.16 g, EDTA.3Na 0.2 g,
NaCI 3.3 g, N-ethyl-N-sulfopropyl-m-toluidine 0.14 g, ascorbate oxidase (TOYOBO ASO-311) 0.02 g, sarcosine oxidase (TOYOBO SAO-341).
6g, creatine amidinohydrolase (Toyobo C
RH-221) 2.7 g was uniformly mixed in a low humidity chamber to prepare a liquid reagent raw material. Second reagent (1 L portion as liquid reagent) disodium hydrogen phosphate 11.92 g, potassium dihydrogen phosphate 2.16 g, 4-aminoantipyrine 0.1.
4g, peroxidase (TOYOBO PEO-301)
0.07 g and 1.2 g of creatinine amide hydrolase (CNH-311 manufactured by Toyobo) were uniformly mixed in a low humidity chamber to prepare a liquid reagent raw material. -20 in the state of a liquid reagent and a liquid reagent raw material obtained by immediately dissolving the above raw material with the following dissolution liquid
The solution was stored at 0 ° C for 1 year, and after storage, a 5 mg / dL creatinine aqueous solution was measured using a liquid reagent dissolved in the following solution.

【0035】〈溶解液〉 第1試薬用溶解液 PIPES 50mM(pH7.5)、カタラーゼ(東
洋紡製CAO−509)200単位/mL、トリトンX
−100 0.5% 第2試薬用溶解液 PIPES 50mM(pH7.5)、トリトンX−1
00 0.5%
<Dissolution> Dissolution for the first reagent PIPES 50 mM (pH 7.5), catalase (CAO-509 manufactured by Toyobo) 200 units / mL, Triton X
-100 0.5% Second reagent solution PIPES 50 mM (pH 7.5), Triton X-1
00 0.5%

【0036】〈測定法〉日立7170形自動分析機を用
いた。試料4μLに第一試薬 180μL添加し37℃
にて5分間インキュベーションし第一反応とした。その
後第二試薬を60μL添加し5分間インキュベーション
し第二反応とした。第一反応および第二反応の吸光度を
液量補正した各吸光度の差をとる2ポイントエンド法で
546nmにおける吸光度を測定した。結果は、精製水
の測定吸光度を差し引いた測定吸光度(感度)として求
めた。
<Measurement method> A Hitachi 7170 type automatic analyzer was used. 180 μL of the first reagent was added to 4 μL of the sample and 37 ° C.
It was incubated for 5 minutes in the reaction to make it the first reaction. After that, 60 μL of the second reagent was added and incubated for 5 minutes to make a second reaction. The absorbance at 546 nm was measured by a 2-point end method in which the absorbance of the first reaction and the absorbance of the second reaction were liquid-corrected and the difference between the absorbances was taken. The result was determined as the measured absorbance (sensitivity) after subtracting the measured absorbance of purified water.

【0037】結果 表2に示す。結果は液状試薬原料
を作製後直ちに溶解した試薬(実施例3−)の測定感
度を100としたときの、作製後−20℃、1年間保存
した液状試薬原料を復元した試薬(実施例3−)の相
対感度を示す。調製後から復元後までの良好な保存安定
性を確認できた。
Results are shown in Table 2. The results show that when the measurement sensitivity of the reagent (Example 3-) in which the liquid reagent raw material was immediately dissolved after preparation was set to 100, the reagent obtained by restoring the liquid reagent raw material stored at -20 ° C for 1 year after preparation (Example 3- ) Shows the relative sensitivity of. Good storage stability from the preparation to the restoration was confirmed.

【0038】[0038]

【表2】 [Table 2]

【0039】(実施例4)実施例3で復元した液状試薬
を10℃で1年間保存し実施例3と同様に5mg/dL
のクレアチニン水溶液を測定した。方法は実施例3と同
様に行った。
Example 4 The liquid reagent reconstituted in Example 3 was stored at 10 ° C. for 1 year and stored in the same manner as in Example 3 at 5 mg / dL.
The creatinine aqueous solution was measured. The method was the same as in Example 3.

【0040】結果 表2に示す。実施例4−、は
各々実施例3−、の溶解後の試薬をさらに10℃、
1年間保存したときの相対感度を示す。復元後の良好な
保存安定性を確認できた。
Results are shown in Table 2. In Example 4-, the reagents after dissolution in Example 3-are further added at 10 ° C,
The relative sensitivity when stored for 1 year is shown. It was possible to confirm good storage stability after restoration.

【0041】(実施例5)下記の2試薬からなる中性脂
肪測定液状試薬原料を作製した。 〈中性脂肪測定液状試薬原料の調製〉 第1試薬(液状試薬として1L分) トリスヒドロキシアミノメタン塩酸塩(TRIZMA
PRE−SET CRYSTALS pH7.0) 1
5g、EDTA・2Na 0.05g、塩化ナトリウム
5.0g、4−アミノアンチピリン 0.1g、グリ
セロールキナーゼ(東洋紡製GYK−311) 0.0
35g、グリセロリン酸オキシダーゼ(東洋紡製G3O
−311) 0.4g、アスコルビン酸オキシダーゼ
(東洋紡製ASO−311) 0.02g、フラビンア
デニンジヌクレオチド 0.006g、アデノシン3リ
ン酸 1.1g、CHAPS 1gを低湿度室にて均一
に混合し液状試薬原料とした。 第2試薬(液状試薬として1L分) リン酸水素2ナトリウム 11.92g、リン酸2水素
カリウム 2.16g、EDTA・2Na 0.05
g、塩化カルシウム 0.02g、N−エチル−N−ス
ルホプロピル−m−アニシジン 0.6g、フェロシア
ン化カリウム 0.03g、ペルオキシダーゼ(東洋紡
製PEO−301) 0.04g、リポプロテインリパ
ーゼ(東洋紡製LPL−314) 1.2g、アデノシ
ン3リン酸0.1g、CHAPS 1gを低湿度室にて
均一に混合し液状試薬原料とした。上記原料を直ちに下
記溶解液で溶解した液状試薬および液状試薬原料の状態
で37℃で2週間保存し、保存後下記溶解液で溶解した
液状試薬を用い、200mg/dLのトリオレイン水溶
液を測定した。
Example 5 A raw material for a liquid reagent for measuring neutral fat consisting of the following two reagents was prepared. <Preparation of Neutral Fat Measuring Liquid Reagent Raw Material> First Reagent (1 L as Liquid Reagent) Trishydroxyaminomethane Hydrochloride (TRIZMA
PRE-SET CRYSTALS pH 7.0) 1
5 g, EDTA.2Na 0.05 g, sodium chloride 5.0 g, 4-aminoantipyrine 0.1 g, glycerol kinase (Toyobo GYK-311) 0.0
35 g, glycerophosphate oxidase (Toyobo G3O
-311) 0.4 g, ascorbate oxidase (ASO-311 manufactured by Toyobo) 0.02 g, flavin adenine dinucleotide 0.006 g, adenosine triphosphate 1.1 g, and CHAPS 1 g are uniformly mixed in a low humidity chamber to be liquid. It was used as a reagent raw material. Second reagent (1 L portion as liquid reagent) disodium hydrogen phosphate 11.92 g, potassium dihydrogen phosphate 2.16 g, EDTA.2Na 0.05
g, calcium chloride 0.02 g, N-ethyl-N-sulfopropyl-m-anisidine 0.6 g, potassium ferrocyanide 0.03 g, peroxidase (TOYOBO PEO-301) 0.04 g, lipoprotein lipase (TOYOBO LPL- 314) 1.2 g, adenosine triphosphate 0.1 g, and CHAPS 1 g were uniformly mixed in a low humidity chamber to prepare a liquid reagent raw material. The above raw material was immediately stored in a liquid reagent dissolved in the following dissolution liquid and the state of the liquid reagent raw material at 37 ° C. for 2 weeks, and after storage, a 200 mg / dL triolein aqueous solution was measured using the liquid reagent dissolved in the following dissolution liquid. .

【0042】〈溶解液〉 第1試薬用溶解液 カタラーゼ(東洋紡製CAO−509) 200単位/
mL、塩化マグネシウム0.2g/L 第2試薬用溶解液 塩化マグネシウム 0.6g/L
<Dissolution> Dissolution liquid catalase for the first reagent (CAO-509 manufactured by Toyobo) 200 units /
mL, Magnesium chloride 0.2 g / L Solution for second reagent Magnesium chloride 0.6 g / L

【0043】〈測定法〉日立7170形自動分析機を用
いた。試料2.1μLに第一試薬 180μL添加し3
7℃にて5分間インキュベーションし第一反応とした。
その後第二試薬を90μL添加し5分間インキュベーシ
ョンし第二反応とした。第一反応および第二反応の吸光
度を液量補正した各吸光度の差をとる2ポイントエンド
法で600nmにおける吸光度を測定した。結果は、精
製水の測定吸光度を差し引いた測定吸光度(感度)とし
て求めた。
<Measurement method> A Hitachi 7170 type automatic analyzer was used. 180 μL of the first reagent was added to 2.1 μL of the sample and 3
Incubation at 7 ° C for 5 minutes was used as the first reaction.
After that, 90 μL of the second reagent was added and incubated for 5 minutes to give a second reaction. The absorbance at 600 nm was measured by the 2-point end method in which the absorbance of the first reaction and the absorbance of the second reaction were liquid-corrected and the difference between the absorbances was taken. The result was determined as the measured absorbance (sensitivity) after subtracting the measured absorbance of purified water.

【0044】結果 表3に示す。結果は液状試薬原料
を作製後直ちに溶解した試薬(実施例5−)の測定感
度を100としたときの、作製後37℃、2週間保存し
た液状試薬原料を復元した試薬(実施例5−)の相対
感度を示す。調製後から復元までの良好な保存安定性を
確認できた。
Results are shown in Table 3. The results show that when the measurement sensitivity of the reagent (Example 5-) in which the liquid reagent raw material was immediately dissolved after preparation was 100, the liquid reagent raw material stored at 37 ° C for 2 weeks after preparation was restored (Example 5-). The relative sensitivity of Good storage stability from the preparation to the restoration was confirmed.

【0045】[0045]

【表3】 [Table 3]

【0046】(実施例6)実施例5で復元した液状試薬
を35℃で1週間保存し実施例5と同様に200mg/
dLのトリオレイン水溶液を測定した。方法は実施例5
と同様に行った。
Example 6 The liquid reagent reconstituted in Example 5 was stored at 35 ° C. for 1 week and then stored in the same manner as in Example 5 at 200 mg / mg.
An aqueous dL solution of triolein was measured. The method is Example 5
I went the same way.

【0047】結果 表3に示す。実施例6−、は
各々実施例5−、の試薬をさらに35℃、1週間保
存したときの相対感度の実施例3−を100としたと
きの相対値を示す。復元後の良好な保存安定性を確認で
きた。
Results are shown in Table 3. Example 6- shows the relative value when the reagent of Example 5- was further stored at 35 ° C. for 1 week, and the relative sensitivity when Example 3-was 100. It was possible to confirm good storage stability after restoration.

【0048】(実施例7)下記の2試薬からなる総コレ
ステロール測定液状試薬原料を作製した。 〈総コレステロール測定液状試薬原料の調製〉 第1試薬(液状試薬として1L分) リン酸水素2ナトリウム 8.67g、リン酸2水素カ
リウム 5.29g、EDTA・3Na 0.1g、塩
化ナトリウム 14.6g、塩化カルシウム 0.02
g、N−エチル−N−スルホプロピル−m−アニシジン
0.2g、コレステロールエステラーゼ(東洋紡製C
OE−311) 0.01g、ペルオキシダーゼ(東洋
紡製PEO−301) 0.02g、アスコルビン酸オ
キシダーゼ(東洋紡製ASO−311) 0.02g、
CHAPS 1gを低湿度室にて均一に混合し液状試薬
原料とした。 第2試薬(液状試薬として1L分) リン酸水素2ナトリウム 8.67g、リン酸2水素カ
リウム 5.29g、EDTA・3Na 0.2g、ア
ジ化ナトリウム 0.05g、4−アミノアンチピリン
0.2g、フェロシアン化カリウム 0.015g、
コレステロールオキシダーゼ(東洋紡製COO−31
1) 0.04g、CHAPS 1gを低湿度室にて均
一に混合し液状試薬原料とした。上記原料を直ちに下記
溶解液で溶解した液状試薬および液状試薬原料の状態で
37℃で2週間保存し、保存後下記溶解液で溶解した液
状試薬を用い、200mg/dLコレステロール水溶液
を測定した。
Example 7 A liquid reagent raw material for measuring total cholesterol consisting of the following two reagents was prepared. <Preparation of Liquid Reagent Raw Material for Measuring Total Cholesterol> First Reagent (1 L as Liquid Reagent) 8.67 g disodium hydrogen phosphate, 5.29 g potassium dihydrogen phosphate, 0.1 g EDTA.3Na, 14.6 g sodium chloride , Calcium chloride 0.02
g, N-ethyl-N-sulfopropyl-m-anisidine 0.2 g, cholesterol esterase (manufactured by Toyobo C
OE-311) 0.01 g, peroxidase (TOYOBO PEO-301) 0.02 g, ascorbate oxidase (TOYOBO ASO-311) 0.02 g,
1 g of CHAPS was uniformly mixed in a low humidity chamber to prepare a liquid reagent raw material. Second reagent (1 L portion as liquid reagent) 8.67 g of disodium hydrogen phosphate, 5.29 g of potassium dihydrogen phosphate, 0.2 g of EDTA.3Na, 0.05 g of sodium azide, 0.2 g of 4-aminoantipyrine, 0.015 g of potassium ferrocyanide,
Cholesterol oxidase (TOYOBO COO-31
1) 0.04 g and CHAPS 1 g were uniformly mixed in a low humidity chamber to prepare a liquid reagent raw material. The above raw materials were immediately stored in a liquid reagent dissolved in the following dissolution liquid and a liquid reagent raw material at 37 ° C. for 2 weeks, and after storage, a 200 mg / dL cholesterol aqueous solution was measured using the liquid reagent dissolved in the following dissolution liquid.

【0049】〈溶解液〉 第1試薬用溶解液 塩化マグネシウム 0.8g/L 第2試薬用溶解液 精製水<Solution> First reagent solution Magnesium chloride 0.8g / L Second reagent solution purified water

【0050】〈測定法〉日立7170形自動分析機を用
いた。試料2.1μLに第一試薬 180μL添加し3
7℃にて5分間インキュベーションし第一反応とした。
その後第二試薬を90μL添加し5分間インキュベーシ
ョンし第二反応とした。第一反応および第二反応の吸光
度を液量補正した各吸光度の差をとる2ポイントエンド
法で600nmにおける吸光度を測定した。結果は、精
製水の測定吸光度を差し引いた測定吸光度(感度)とし
て求めた。
<Measurement method> A Hitachi 7170 type automatic analyzer was used. 180 μL of the first reagent was added to 2.1 μL of the sample and 3
Incubation at 7 ° C for 5 minutes was used as the first reaction.
After that, 90 μL of the second reagent was added and incubated for 5 minutes to give a second reaction. The absorbance at 600 nm was measured by the 2-point end method in which the absorbance of the first reaction and the absorbance of the second reaction were liquid-corrected and the difference between the absorbances was taken. The result was determined as the measured absorbance (sensitivity) after subtracting the measured absorbance of purified water.

【0051】結果 表4に示す。結果は液状試薬原料
を作製後直ちに溶解した試薬(実施例7−)の測定感
度を100としたときの、作製後37℃、2週間保存し
た液状試薬原料を復元した試薬(実施例7−)の相対
感度を示す。調製後から復元までの良好な保存安定性を
確認できた。
Results are shown in Table 4. The results show that when the measurement sensitivity of the reagent (Example 7-) in which the liquid reagent raw material was immediately dissolved after preparation was 100, the liquid reagent raw material stored at 37 ° C for 2 weeks after preparation was restored (Example 7-). The relative sensitivity of Good storage stability from the preparation to the restoration was confirmed.

【0052】[0052]

【表4】 [Table 4]

【0053】(実施例8)実施例7で復元した液状試薬
を35℃で1週間保存し実施例7と同様に200mg/
dLコレステロール水溶液を測定した。方法は実施例7
と同様に行った。
(Example 8) The liquid reagent reconstituted in Example 7 was stored at 35 ° C for 1 week and stored in the same manner as in Example 7 at 200 mg / mg.
The dL cholesterol aqueous solution was measured. The method is Example 7.
I went the same way.

【0054】結果 表4に示す。実施例8−、は
各々実施例7−、の試薬をさらに35℃、1週間保
存したときの測定感度の実施例7−を100としたと
きの相対値を示す。復元後の良好な保存安定性を確認で
きた。
Results are shown in Table 4. Example 8- shows the relative value when the reagent of Example 7- was further stored at 35 ° C. for 1 week, and the measurement sensitivity of Example 7- was set to 100. It was possible to confirm good storage stability after restoration.

【0055】(実施例9)実施例3の2試薬からなるク
レアチニン測定液状試薬原料より、第一試薬、第二試薬
各々無作為にN=3で液状試薬として第一試薬1.05
2g(液状試薬として50mL分)、第二試薬0.78
8g(液状試薬として50mL分)を70mLの日立7
170形自動分析機専用ボトル(ポリエチレン製)に秤
量し、実施例3の溶解液を各々50mLで溶解した液状
試薬を用い、実施例3と同様に5mg/dLのクレアチ
ニン水溶液を測定した。
(Example 9) Creatinein measurement liquid reagent raw material consisting of two reagents of Example 3 was used, and the first reagent and the second reagent were randomly N = 3 and the first reagent was 1.05 as the liquid reagent.
2 g (50 mL for liquid reagent), 0.78 second reagent
8g (50mL for liquid reagent) to 70mL Hitachi 7
In the same manner as in Example 3, 5 mg / dL of creatinine aqueous solution was measured using a liquid reagent prepared by weighing in a bottle (made of polyethylene) dedicated to the 170 type automatic analyzer and dissolving the solution of Example 3 in 50 mL each.

【0056】結果 表5に示す。実施例9−、、
は実施例9−の測定感度を100とした時のN=3
の相対感度を示す。成分が均一に混合されていることを
確認できた。
Results are shown in Table 5. Example 9-,
Is N = 3 when the measurement sensitivity of Example 9 is 100.
The relative sensitivity of It was confirmed that the components were uniformly mixed.

【0057】[0057]

【表5】 [Table 5]

【0058】(実施例10)実施例9で作製した液状試
薬を35℃で1週間保存し、実施例3と同様に5mg/
dLのクレアチニン水溶液を測定した。方法は実施例3
と同様に行った。
(Example 10) The liquid reagent prepared in Example 9 was stored at 35 ° C for 1 week, and 5 mg / mg as in Example 3 was stored.
A dL creatinine aqueous solution was measured. The method is Example 3
I went the same way.

【0059】結果 表5に示す。実施例10−、
、は各々実施例9−、、の液状試薬をさらに
35℃、1週間保存したときの測定感度の実施例9−
を100とした時の相対値を示す。成分が均一に混合さ
れていることを確認できた。
Results are shown in Table 5. Example 10-,
, Are the examples of the measurement sensitivity when the liquid reagents of Examples 9-, and were stored at 35 ° C. for 1 week.
Shows the relative value when 100 is set. It was confirmed that the components were uniformly mixed.

【0060】[0060]

【発明の効果】本発明では、緩衝剤、酵素、補酵素、酵
素基質、色源体、防腐剤、金属塩、界面活性剤、安定化
剤等の成分が溶解されることなく乾燥状態で均一に混合
されることにより、従来の凍結乾燥工程を利用せずに無
調製液状試薬に用いられる簡便かつ安定な液状試薬原料
およびそれを用いた組成物を提供することができた。
INDUSTRIAL APPLICABILITY According to the present invention, components such as a buffer, an enzyme, a coenzyme, an enzyme substrate, a chromogen, an antiseptic, a metal salt, a surfactant and a stabilizer are uniformly dissolved in a dry state. It was possible to provide a simple and stable liquid reagent raw material to be used for an unprepared liquid reagent and a composition using the same, by mixing with a conventional lyophilization step.

フロントページの続き Fターム(参考) 2G045 BB29 BB51 BB54 DA01 DA20 DA42 DA60 FA26 FB01 FB11 GC10 JA07 JA08 4B063 QA01 QQ03 QQ70 QQ76 QQ84 QR02 QR03 QR07 QR50 QR81 QS01 Continued front page    F term (reference) 2G045 BB29 BB51 BB54 DA01 DA20                       DA42 DA60 FA26 FB01 FB11                       GC10 JA07 JA08                 4B063 QA01 QQ03 QQ70 QQ76 QQ84                       QR02 QR03 QR07 QR50 QR81                       QS01

Claims (16)

【特許請求の範囲】[Claims] 【請求項1】2種以上の成分を混合してなる液状試薬原
料の製造において、各成分を溶解することなく乾燥状態
で混合することを特徴とする液状試薬原料の製造方法。
1. A method of producing a liquid reagent raw material, which comprises mixing two or more components in a liquid state without dissolving each component in the production of the liquid reagent raw material.
【請求項2】液状試薬原料が均一に混合されていること
を特徴とする、請求項1記載の液状試薬原料の製造方
法。
2. The method for producing a liquid reagent raw material according to claim 1, wherein the liquid reagent raw material is uniformly mixed.
【請求項3】緩衝剤を少なくとも10%(w/w)含有
する、請求項1、2に記載の液状試薬原料の製造方法。
3. The method for producing a liquid reagent raw material according to claim 1, which contains at least 10% (w / w) of a buffer.
【請求項4】緩衝剤を50%(w/w)以上含有する、
請求項1〜3に記載の液状試薬原料の製造方法。
4. A buffer containing 50% (w / w) or more,
The method for producing a liquid reagent raw material according to claim 1.
【請求項5】2種以上の成分が溶解されることなく乾燥
状態で混合された液状試薬原料組成物。
5. A liquid reagent raw material composition in which two or more components are mixed in a dry state without being dissolved.
【請求項6】液状試薬原料が均一に混合されている請求
項5記載の液状試薬原料組成物。
6. The liquid reagent raw material composition according to claim 5, wherein the liquid reagent raw materials are uniformly mixed.
【請求項7】緩衝剤を少なくとも10%(w/w)含有
する、請求項5、6記載の液状試薬原料組成物。
7. The liquid reagent raw material composition according to claim 5, which contains at least 10% (w / w) of a buffering agent.
【請求項8】緩衝剤を50%(w/w)以上含有する、
請求項5〜7記載の液状試薬原料組成物。
8. A buffer containing 50% (w / w) or more,
The liquid reagent raw material composition according to claim 5.
【請求項9】2種以上の成分が緩衝剤、酵素、補酵素、
酵素基質、色源体、防腐剤、金属塩、界面活性剤、安定
化剤より選ばれた物質である請求項5〜8記載の液状試
薬原料組成物。
9. A buffer, an enzyme, a coenzyme, comprising two or more components.
The liquid reagent raw material composition according to claim 5, which is a substance selected from an enzyme substrate, a chromogen, an antiseptic, a metal salt, a surfactant, and a stabilizer.
【請求項10】所定量の水または試液で溶解して用いら
れる請求項5〜9項記載の液状試薬原料組成物。
10. The liquid reagent raw material composition according to claim 5, which is used by dissolving it in a predetermined amount of water or a reagent solution.
【請求項11】少なくとも2種の成分を混合してなる液
状試薬において、予め少なくとも2種以上の成分よりな
る液状試薬原料を調製して、一定期間保持した後、所定
量の水または試液で溶解して液状試薬を完成させ、測定
に供せしめる液状試薬原料であって、該液状試薬原料を
37℃、2週間保存後、所定量の水または試液で溶解し
た液状試薬の測定感度が、保存前の測定感度に対し80
%以上保持し、さらに該液状試薬を35℃、1週間保存
した後の測定感度が、保存前の測定感度に対し80%以
上保持することを特徴とする請求項5〜10項記載の液
状試薬原料組成物。
11. A liquid reagent comprising a mixture of at least two components, a liquid reagent raw material comprising at least two components is prepared in advance, held for a certain period, and then dissolved with a predetermined amount of water or a test solution. A liquid reagent raw material to be used for measurement after completing the liquid reagent by storing the liquid reagent raw material at 37 ° C. for 2 weeks and then measuring the sensitivity of the liquid reagent dissolved in a predetermined amount of water or a test solution before storage. 80 for measurement sensitivity
% Or more, and the measurement sensitivity after the liquid reagent is stored at 35 ° C. for 1 week is 80% or more relative to the measurement sensitivity before storage, and the liquid reagent according to claim 5 or 10. Raw material composition.
【請求項12】液状試薬原料を分析機で用いる容器に所
定の用量を小分封し、該容器に所定量の水または試液を
加え溶解して用いられる請求項5〜11記載の液状試薬
原料組成物。
12. The liquid reagent raw material composition according to claim 5, wherein the liquid reagent raw material composition is used by subdividing a predetermined dose into a container used in an analyzer, and adding a predetermined amount of water or a test solution to the container to dissolve it. object.
【請求項13】液状試薬がクレアチニン測定試薬である
請求項5〜12記載の液状試薬原料組成物。
13. The liquid reagent raw material composition according to claim 5, wherein the liquid reagent is a creatinine measuring reagent.
【請求項14】液状試薬が中性脂肪測定試薬である請求
項5〜12記載の液状試薬原料組成物。
14. The liquid reagent raw material composition according to claim 5, wherein the liquid reagent is a neutral fat measuring reagent.
【請求項15】液状試薬がコレステロール測定試薬であ
る請求項5〜12記載の液状試薬原料組成物。
15. The liquid reagent raw material composition according to claim 5, wherein the liquid reagent is a cholesterol measuring reagent.
【請求項16】液状試薬が尿酸測定試薬である請求項5
〜12記載の液状試薬原料組成物。
16. The liquid reagent is a uric acid measuring reagent.
12. The liquid reagent raw material composition according to 12 above.
JP2001233939A 2001-08-01 2001-08-01 Method for manufacturing liquid-like reagent raw material Withdrawn JP2003043035A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001233939A JP2003043035A (en) 2001-08-01 2001-08-01 Method for manufacturing liquid-like reagent raw material

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001233939A JP2003043035A (en) 2001-08-01 2001-08-01 Method for manufacturing liquid-like reagent raw material

Publications (1)

Publication Number Publication Date
JP2003043035A true JP2003043035A (en) 2003-02-13

Family

ID=19065643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001233939A Withdrawn JP2003043035A (en) 2001-08-01 2001-08-01 Method for manufacturing liquid-like reagent raw material

Country Status (1)

Country Link
JP (1) JP2003043035A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005278626A (en) * 2004-03-30 2005-10-13 Shino Test Corp Method for stabilizing enzymatic measuring reagent
JP2005292110A (en) * 2004-03-31 2005-10-20 Shino Test Corp Method of restraining nonspecific coloring
WO2006030866A1 (en) * 2004-09-16 2006-03-23 Denka Seiken Co., Ltd. Method of quantitative determination of uric acid
WO2006054519A1 (en) * 2004-11-17 2006-05-26 Kyowa Medex Co., Ltd. Standard item for fractional determination of component of lipoprotein
WO2021054432A1 (en) * 2019-09-19 2021-03-25 積水メディカル株式会社 Method for measuring target component using enzyme, and measurement reagent

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005278626A (en) * 2004-03-30 2005-10-13 Shino Test Corp Method for stabilizing enzymatic measuring reagent
JP4639287B2 (en) * 2004-03-30 2011-02-23 株式会社シノテスト Stabilization method for enzymatic measurement reagents
JP2005292110A (en) * 2004-03-31 2005-10-20 Shino Test Corp Method of restraining nonspecific coloring
JP4691627B2 (en) * 2004-03-31 2011-06-01 株式会社シノテスト Method for suppressing non-specific color development
WO2006030866A1 (en) * 2004-09-16 2006-03-23 Denka Seiken Co., Ltd. Method of quantitative determination of uric acid
WO2006054519A1 (en) * 2004-11-17 2006-05-26 Kyowa Medex Co., Ltd. Standard item for fractional determination of component of lipoprotein
JP4704355B2 (en) * 2004-11-17 2011-06-15 協和メデックス株式会社 Standard product for fractional determination of components in lipoproteins
WO2021054432A1 (en) * 2019-09-19 2021-03-25 積水メディカル株式会社 Method for measuring target component using enzyme, and measurement reagent
JPWO2021054432A1 (en) * 2019-09-19 2021-03-25
JP7026293B2 (en) 2019-09-19 2022-02-25 積水メディカル株式会社 Measurement method and measurement reagent of target component using enzyme

Similar Documents

Publication Publication Date Title
Schoot et al. Studies on (Na++ K+)-activated ATPase. XLII. Evidence for two classes of essential sulfhydryl groups
JP2003043035A (en) Method for manufacturing liquid-like reagent raw material
US5278044A (en) Stable aqueous NADH reagent and kit
JP2003066040A (en) Preparation method and composition for liquid reagent raw material
Chung et al. Lysosomal membrane adenosine triphosphatase; solubilization and partial characterization
JP4639287B2 (en) Stabilization method for enzymatic measurement reagents
US6579707B2 (en) Stabilization of enzymes during freezing
JPH07236483A (en) Stabilization of physiologically active protein
Angleton et al. Preparation by direct metal exchange and kinetic study of active site metal substituted class I and class II Clostridium histolyticum collagenases
EP2857503B1 (en) Method for stabilizing ascorbic acid oxidase
JP2596911B2 (en) Stabilized isoenzyme control product
JP3695596B2 (en) Biological component measurement method and reagent composition for measurement
Whitner et al. Stability of creatine kinase-3 in lyophilized materials.
US7214481B2 (en) Charcoal stabilization of phenyl phosphates
EP1136564B1 (en) Reagent for glutamic-pyruvic transaminase assay
JP6698651B2 (en) Kit containing ATP-diphosphohydrolase for detecting bacterial ATP in a sample
Granjeiro et al. Essential sulfhydryl groups in the active site of castor bean (Ricinus communis) seed acid phosphatase
JP4797349B2 (en) Method of stabilizing reagent using vitamin B6 enzyme and reagent
JPH11164699A (en) Stabilization of trypsin, improvement of trypsin enzyme activity, and kit for assay of trypsin enzyme activity
CN1621522B (en) Cholesterin dehydrogenase stabilization method, composition containing cholesterin dehydrogenase and cholesterin detection reagent
JPH09248200A (en) Reagent for assaying glucose
JP2004242525A (en) Method for stabilizing enzyme
Harmon Determination of the orientation of membrane vesicles derived from mitochondria
JP2002051769A (en) Liquid reagent useful for measuring nonesterified fatty acid
JPH04335887A (en) Stabilization of xanthine oxidase

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080630

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100526